A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Commentary|Articles|June 6, 2025
Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress
Author(s)Chris Ryan
Fact checked by: Ashling Wahner , Jax DiEugenio
Experts highlight key abstracts to watch for at the 2025 EHA Congress.
Advertisement
Advertisement
The
Related to this article
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The supplemental new drug application was submitted under the accelerated approval pathway with a request for priority review.
The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.
Advertisement
Advertisement